GlobeNewswire Inc | Nov 23, 2020 08:00AM EST

November 23, 2020

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the 32nd Annual Piper Sandler Virtual Healthcare Conference and the 3rd Annual Evercore ISI HealthCONx Conference that are being held in December 2020.

Event: 32nd Annual Piper Sandler Virtual Healthcare ConferenceDate: December 1^st- 3^rd A webcast presentation will be available via the Piper SandlerWebcast: conference site (click here) from November 23^rd to December 3^rd. In addition, the webcast will be posted on Avadel?s website, www.avadel.com, for 90 days from being made available. Event: 3rd Annual Evercore ISI HealthCONx ConferenceDate: Thursday, December 3^rd Time: 9:15 a.m. ET A webcast will be available at (click here), as well as on theWebcast: ?Investors? section of the Company?s website at www.avadel.com. A replay of the webcast will be available on Avadel?s website for 90 days following the presentation.

About Avadel Pharmaceuticals plc:Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Companys primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Contacts:

Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915-2564 Email: tim@lifesciadvisors.com